Source |
Code |
Name |
Case count |
Share of cases (%) |
REIMB |
REIMB_KELA(317)_ICD10(L20) |
Topical pimecrolimus and tacrolimus, Atopic dermatitis |
2156 |
|
REIMB |
REIMB_KELA(317)_ICD10(L200) |
Topical pimecrolimus and tacrolimus, Besnier's prurigo |
1235 |
|
REIMB |
REIMB_KELA(134)_ICD10(L400) |
General erythroderma, Psoriasis vulgaris |
219 |
|
REIMB |
REIMB_KELA(134)_ICD10(L26) |
General erythroderma, Exfoliative dermatitis |
102 |
|
REIMB |
REIMB_KELA(395)_ICD10(L200) |
Dupilumab, Besnier's prurigo |
80 |
|
REIMB |
REIMB_KELA(395)_ICD10(L20) |
Dupilumab, Atopic dermatitis |
77 |
|
REIMB |
REIMB_KELA(134)_ICD9(NA) |
General erythroderma, Name not found |
75 |
|
REIMB |
REIMB_KELA(134)_ICD10(L20) |
General erythroderma, Atopic dermatitis |
59 |
|
REIMB |
REIMB_KELA(395)_ICD10(J45) |
Dupilumab, Asthma |
39 |
|
REIMB |
REIMB_KELA(134)_ICD8(NA) |
General erythroderma, Name not found |
24 |
|
REIMB |
REIMB_KELA(395)_ICD10(J33) |
Dupilumab, Nasal polyp |
24 |
|
REIMB |
REIMB_KELA(134)_ICD10(L200) |
General erythroderma, Besnier's prurigo |
20 |
|
REIMB |
REIMB_KELA(317)_ICD10(L209) |
Topical pimecrolimus and tacrolimus, Atopic dermatitis, unspecified |
17 |
|
REIMB |
REIMB_KELA(134)_ICD9(6961A) |
General erythroderma, Psoriasis and similar disorders, Other psoriasis |
15 |
|
REIMB |
REIMB_KELA(395)_ICD10(J330) |
Dupilumab, Polyp of nasal cavity |
12 |
|
REIMB |
REIMB_KELA(134)_ICD10(NA) |
General erythroderma, Name not found |
10 |
|
REIMB |
REIMB_KELA(395)_ICD10(J451) |
Dupilumab, Nonallergic asthma |
10 |
|
REIMB |
REIMB_KELA(395)_ICD10(J450) |
Dupilumab, Predominantly allergic asthma |
9 |
|
REIMB |
REIMB_KELA(134)_ICD10(L53) |
General erythroderma, Other erythematous conditions |
6 |
|